-
Sacituzumab: Exploring its Role in Cancer Research and the Rise of Biosimilars(Post)
Key Facts About SacituzumabWhat is Sacituzumab?Sacituzumab is an antibody-drug conjugate (ADC) that targets the tumor-associated antigen Trop-2, used to treat various cancers, including
Ianalumab: Exploring Its Mechanism, Clinical Applications, and Research Potential(Post)Quick Facts About IanalumabWhat is Ianalumab?Ianalumab is a monoclonal antibody currently being investigated for its potential in treating autoimmune diseases, particularly lupus and imm
Icatolimab: Revolutionizing the Fight Against Cancer via CD47 Targeting(Post)Quick Facts About IcatolimabWhat is Icatolimab?Icatolimab is a monoclonal antibody designed to target CD47, a protein that cancer cells use to evade immune detection.How does Icatolimab
Cabiralizumab: Unlocking the Potential of Anti-CSF1R Therapy(Post)What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c
Trastuzumab: Revolutionizing HER2-Positive Cancer Treatment & Research(Post)Quick Facts About TrastuzumabWhat is Trastuzumab?Trastuzumab is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2 protein, re
Ulocuplumab: Targeting CXCR4 in Cancer Research and Beyond(Post)Quick Facts About UlocuplumabWhat is Ulocuplumab?Ulocuplumab is an investigational monoclonal antibody targeting CXCR4, a chemokine receptor involved in tumor progression and immune cell
Eldelumab: Unlocking the Potential of Anti-TNFSF14 in Inflammatory Diseases(Post)Quick Facts About EldelumabWhat is Eldelumab?Eldelumab is a monoclonal antibody targeting TNFSF14 (LIGHT), a key regulator in immune system signaling, with potential applications in infl
Durvalumab: Advancing Immunotherapy in Cancer Treatment(Post)Quick Facts About DurvalumabWhat is Durvalumab?Durvalumab (Imfinzi) is a PD-L1 checkpoint inhibitor used in immunotherapy to treat various cancers, including non-small cell lung cancer (
Begelomab: Mechanism of Action, Clinical Applications & Biosimilars(Post)Quick Facts About BegelomabWhat is Begelomab?Begelomab is a monoclonal antibody that targets CD26, a key molecule involved in immune regulation. It has been studied for its potential app
Évitez la rupture de réactifs en 6 actions pour gestionnaires labo(Post)Évitez la rupture de réactifs en 6 actions pour gestionnaires labo Pour éviter la majorité des ruptures de réactifs, auditez votre inventaire critique, fixez des seuils de commande calculés sur le dé
Barrett’s Oesophagus to Oesophageal Adenocarcinoma – Review(Post)Oesophageal Adenocarcinoma is on the rise globally affecting more than 450,000 people worldwide (Pennathur, Gibson et al. 2013). Once diagnosed overall 5-year survival ranges from 15 % to 2
Diabetic Retinopathy: premature cellular senescence and microvascular dysfunction(Post)By Pietro Maria Bertelli, PhD Candidate, Queens University Belfast Introduction Eye complications are very frequent in patients with diabetes, and thi
RIPA Buffer Recipe - Mandarin(Page)RIPA 缓冲液配方与细胞裂解方案(中文) | Assay Genie<
ELISA バッファーとレシピ(Page)ELISA バッファーとレシピ | Assay Genie | Assay Genie
OX40 Agonists: Revitalizing the Immune Response in Cancer(Post)Cancer immunotherapy has revolutionized treatment options, offering strategies to harness the immune system to target and destroy tumors. One emerging area of interest is the use of OX40
Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research(Post)What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers
Basiliximab: Mechanism, Clinical Applications, and Research Advancements(Post)Quick Facts About BasiliximabWhat is Basiliximab?Basiliximab is a monoclonal antibody targeting the CD25 subunit of the IL-2 receptor, primarily used to prevent organ transplant rejectio
Ivuxolimab: Redefining Cancer Immunotherapy and Research(Post)Quick Facts About IvuxolimabWhat is ivuxolimab?Ivuxolimab is a monoclonal antibody targeting CD47, a "don't eat me" signal that cancer cells exploit to evade immune destruction.How does
Natalizumab: Mechanism, Applications, and Emerging Research in Multiple Sclerosis and Crohn's Disease(Post)Quick Facts About NatalizumabWhat is Natalizumab?Natalizumab is a monoclonal antibody used to treat multiple sclerosis (MS) and Crohn's disease. It works by blocking immune cells from at
Zilovertamab: Unlocking the Potential of ROR1-Targeted Therapy(Post)Quick Facts About ZilovertamabWhat is Zilovertamab?Zilovertamab is a monoclonal antibody targeting ROR1, a receptor tyrosine kinase overexpressed in hematologic cancers and solid tumors.